Archive for the ‘Regen BioPharma Inc’ Category

Regen BioPharma Inc.

December 18th, 2015 | Posted in 2015, Regen BioPharma Inc

Regen BioPharma Inc., La Mesa, received clearance from the FDA to begin clinical trials of HemaXellerate, its lead drug candidate. HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning. Regen BioPharma’s initial Phase I clinical trial will treat aplastic anemia patients who haven’t […]

Regen BioPharma Inc

April 22nd, 2015 | Posted in 2015, Regen BioPharma Inc

Regen BioPharma, San Diego, filed a patent application for a therapy for the treatment of myelodysplastic syndrome. The syndrome is a collection of diseases including aplastic anemia, a condition in which the bone marrow does not produce a sufficient number of blood cells.

Regen BioPharma Inc

May 1st, 2012 | Posted in 2012, Regen BioPharma Inc

Regen BioPharma Inc. – Is a new subsidiary formed from San Diego’s Bio-Matrix Scientific Group.  The new company, Regen BioPharma,  has developed a vertically integrated structure for acquiring patents, performing accelerating preclinical and clinical development, and licensing or selling technology developed to large pharma companies in the area of stem cells.  The subsidiary has to […]